Join
Live feed
·
PRReleasevia Quantisnow
Harmony Biosciences Holdings Inc. logo

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

ByQuantisnow·Wall Street's wire, on your screen.
HRMY· Harmony Biosciences Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HRMY (Harmony Biosciences Holdings Inc.) and more on Quantisnow.